CVS: Signify Health Adds In-Home Chronic Kidney Disease Testing to Offerings

What You Should Know:

– Today, Signify Health announced the addition of a new comprehensive in-home kidney health testing/evaluation as part of their diagnostic and preventive service offerings.

– This is Signify’s latest diagnostic offering for IHEs since the addition of spirometry screenings for chronic obstructive pulmonary disease (COPD) announced in the fall of 2022. The company’s growth in diagnostic and preventive services demonstrates their ability to capture a growing number of health risks earlier and from the comfort of a member’s home.

Expands In-Home Diagnostics & Preventive Service Offering

Chronic kidney diseases (CKD) currently impacts 37 million U.S. adults, most of whom go undiagnosed, leading to even greater downstream costs. The exam will be conducted by one of Signify Health’s 10,000 credentialed providers as part of an in-home health evaluation (IHE), available to Medicare Advantage members at no additional cost, across all 50 states. Results of the kidney health evaluation, including urinalysis (uACR) and estimated glomerular filtration rate (eGFR), provide clinicians and members with information to help them determine the treatment and management plan that is best for them.

This plan may include: additional testing, lifestyle changes, pharmacological treatment, and a referral to a nephrologist for further evaluation and co-management. The new offering has the potential to proactively assess the kidney health of millions of Medicare members Signify reaches through its IHEs, and will drive early diagnosis and management of (CKD).

diagnostics